MedTrace Logo

IUCD Insertion in Patients Delivered by Cesarean Section

NCT06864078 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2025-03-07

No results posted yet for this study

Summary

Long-acting reversible contraceptive (LARC) methods, including intrauterine devices (IUDs), are highly effective and safe options for preventing unintended pregnancies. IUDs have failure rates below one percent, making them one of the most reliable forms of contraception available.

They are suitable for females of all ages, including adolescents and nulliparous women, and offer long-term protection without requiring daily adherence, unlike oral contraceptives. Increasing the utilization of IUDs can provide a safe, long-acting, highly effective, and reversible method of contraception, reducing the incidence of unintended pregnancies and associated complications.

Conditions

  • IUD

Interventions

DEVICE

IUD Insertion during Cesarean Section

to evaluate the analgesic effect of diclofenac potassium and lidocaine gel applied to the posterior vaginal fornix before IUD insertion in women who had previously undergone cesarean section. By assessing the efficacy of this pain management strategy, this study seeks to contribute to the optimization of IUD insertion protocols, improving patient comfort and increasing the acceptance of this highly effective contraceptive method.

DRUG

lidocaine gel and diclofenac potassium tablets

lidocaine gel and diclofenac potassium tablets

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Principal Investigators

  • Yousry Omar Salim El Maraghy, Professor · Obstetrics and Gynecology, Faculty of medicine Al-Azhar University Assuit.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-10
Primary Completion
2024-08-05
Completion
2024-08-10

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06864078 on ClinicalTrials.gov